TMS Co., Ltd. (JP:4891)
:4891
Want to see JP:4891 full AI Analyst Report?
Top Page
TMS Co., Ltd.
(4891)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥133.00
▲(3.10% Upside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by weak recent financial performance—sustained losses, negative cash flow, and declining equity—partially offset by the absence of debt. Technicals add pressure with the stock trading below key moving averages, while valuation offers limited support due to a non-meaningful P/E and no dividend yield data.
Positive Factors
No Debt / Conservative Balance Sheet
A debt-free balance sheet materially lowers solvency risk and provides financing flexibility. For a clinical-stage biotech burning cash, absence of leverage preserves optionality for R&D spending, partnership deals or opportunistic funding without debt-servicing constraints.
Negative Factors
Sustained Losses & Declining Equity
Multi-year operating and net losses with equity erosion (equity down from ~¥3.71B to ~¥2.82B) indicate the company is consuming capital rather than generating returns. Persisting negative ROE (-23% in 2025) undermines internal funding capacity and heightens reliance on external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
No Debt / Conservative Balance Sheet
A debt-free balance sheet materially lowers solvency risk and provides financing flexibility. For a clinical-stage biotech burning cash, absence of leverage preserves optionality for R&D spending, partnership deals or opportunistic funding without debt-servicing constraints.
Read all positive factors
TMS Co., Ltd. (4891) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.56B
Dividend YieldN/A
Average Volume (3M)256.91K
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue GrowthN/A
EPS GrowthN/A
CountryJP
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding45,565,765
10 Day Avg. Volume257,770
30 Day Avg. Volume256,913
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio-7.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-25.28
Revenue Forecast (FY)N/A
TMS Co., Ltd. Business Overview & Revenue Model
Company Description
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (S...
TMS Co., Ltd. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
62
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.95B |
| Gross Profit | -501.00K | -314.40K | -3.71M | -6.95M | -6.60M | 1.74B |
| EBITDA | -1.02B | -836.05M | -655.89M | -937.00M | -513.55M | 1.14B |
| Net Income | -699.20M | -859.27M | -660.55M | -960.04M | -860.92M | 1.08B |
Balance Sheet | ||||||
| Total Assets | 3.21B | 0.00 | 3.03B | 3.55B | 3.79B | 2.74B |
| Cash, Cash Equivalents and Short-Term Investments | 3.18B | 0.00 | 2.92B | 3.45B | 3.58B | 2.60B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 122.98M | 0.00 | 216.78M | 97.69M | 76.16M | 286.78M |
| Stockholders Equity | 3.09B | 0.00 | 2.82B | 3.46B | 3.71B | 2.45B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -782.43M | -524.60M | -826.17M | -702.14M | 1.25B |
| Operating Cash Flow | 0.00 | -779.89M | -493.76M | -822.81M | -688.42M | 1.26B |
| Investing Cash Flow | 0.00 | -2.54M | -30.84M | -3.36M | -13.72M | -16.96M |
| Financing Cash Flow | 0.00 | 640.52M | 919.00K | 688.13M | 1.69B | 246.48M |
TMS Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ¥16.64B | 120.78 | ― | ― | 1.24% | -33.41% | |
56 Neutral | ¥7.82B | 33.49 | ― | ― | 2.99% | -52.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥48.47B | -13.30 | ― | ― | -82.33% | 47.73% | |
49 Neutral | ¥11.31B | -8.14 | ― | ― | -42.49% | -2.37% | |
45 Neutral | ¥19.37B | -11.30 | ― | ― | ― | 11.34% | |
43 Neutral | ¥6.56B | -6.68 | ― | ― | ― | ― |
* Healthcare Sector Average
JP:4891
TMS Co., Ltd.
144.00
13.00
9.92%
JP:4593
Healios KK
359.00
56.00
18.48%
JP:4599
StemRIM Inc.
309.00
-11.00
-3.44%
JP:4978
ReproCELL Inc.
175.00
30.00
20.69%
JP:7096
StemCell Institute
763.00
-531.00
-41.04%
JP:7776
CellSeed Inc.
291.00
-321.00
-52.45%
TMS Co., Ltd. Corporate Events
TMS Enrolls First Japanese Patient in Global Phase II/III Stroke Trial of TMS-007
Feb 19, 2026
TMS Co., Ltd. said it has enrolled the first patient in the Japan cohort of the global Phase II/III ORION trial of TMS-007 (JX10), an intravenous therapy for acute ischemic stroke designed to be given between 4.5 and 24 hours after patients were l...
TMS Co., Ltd. Posts Continued Losses but Maintains Strong Equity Base in Shortened Fiscal Year
Feb 13, 2026
TMS Co., Ltd. reported non-consolidated results for an irregular 10‑month fiscal year ended December 31, 2025, posting operating, ordinary and net losses of ¥696 million, ¥711 million and ¥716 million, respectively. Despite co...
TMS Posts Loss for Transitional Fiscal Year, Withheld 2026 Guidance Amid Ongoing Uncertainty
Feb 13, 2026
TMS Co., Ltd. reported a non-consolidated net loss of ¥716 million for the irregular 10‑month fiscal period ended December 31, 2025, following a prior-period loss, with basic earnings per share at negative ¥16.08. Despite continued...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.